2019
Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma
Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanan M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019, 68: 1676. PMID: 31315892, PMCID: PMC7087395, DOI: 10.1136/gutjnl-2018-317811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsApoptosisCalcium SignalingCarcinogenesisCarcinoma, HepatocellularCell ProliferationCells, CulturedDNA MethylationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansInositol 1,4,5-Trisphosphate ReceptorsLiverLiver NeoplasmsLiver RegenerationMaleMice, KnockoutMiddle AgedSurvival AnalysisConceptsChronic liver diseaseITPR3 expressionLiver cancer cellsLiver diseaseMouse modelFinal common eventCancer cellsSpecimens of patientsIndependent patient cohortsControl liver specimensHuman HCC cellsType 3 InsP3 receptorHuman liver samplesIncreased expression levelCancer deathPatient cohortCommon molecular eventPoor survivalHepatocellular carcinomaLiver specimensNormal liverHCC cellsAbstractTextHCCType 3 isoform
2018
Response to letter to the editor: impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004–2012
McCarty TR, Echouffo-Tcheugui JB, Lange A, Haque L, Njei B. Response to letter to the editor: impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004–2012. Surgery For Obesity And Related Diseases 2018, 14: 726. PMID: 29576483, DOI: 10.1016/j.soard.2018.02.020.Commentaries, Editorials and Letters
2017
Vanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review
Bakhit M, McCarty TR, Park S, Njei B, Cho M, Karagozian R, Liapakis A. Vanishing bile duct syndrome in Hodgkin’s lymphoma: A case report and literature review. World Journal Of Gastroenterology 2017, 23: 366-372. PMID: 28127210, PMCID: PMC5236516, DOI: 10.3748/wjg.v23.i2.366.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic AgentsBile Duct DiseasesBile Ducts, IntrahepaticBiopsyCholangiopancreatography, Magnetic ResonanceCholestasisExomeHepatocyte Growth FactorHigh-Throughput Nucleotide SequencingHodgkin DiseaseHumansHyperbilirubinemiaHypertension, PortalJaundiceLiverLiver Function TestsMaleNeoplasm StagingProto-Oncogene ProteinsSyndromeTomography, X-Ray ComputedConceptsBile duct syndromeHodgkin's lymphomaIntra-hepatic bile ductsBile duct lossBile duct injuryAdverse drug reactionsDifferent pathologic conditionsTransplant evaluationDuct injuryAllograft rejectionClinical recoveryParaneoplastic phenomenonBiliary cirrhosisLiver biopsyLiver failureBile ductAutoimmune diseasesCase reportDrug reactionsEarly recognitionPhysical examPoor responseVBDSHumoral factorsMedical treatment
2015
Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia
Gupta N, Njei B. Syncytial giant cell hepatitis in a patient with chronic lymphocytic leukemia. Journal Of Digestive Diseases 2015, 16: 683-688. PMID: 26147671, PMCID: PMC4824312, DOI: 10.1111/1751-2980.12273.Peer-Reviewed Original ResearchConceptsGiant cell hepatitisChronic lymphocytic leukemiaSyncytial giant cell hepatitisHigh-dose corticosteroidsHistory of chemotherapySuch confounding variablesPediatric populationDrug medicationAutoimmune diseasesLiver enzymesVirus infectionLymphocytic leukemiaHepatitisConfounding variablesPatientsViral particlesDiseaseAdultsSuch casesCorticosteroidsHypogammaglobulinemiaMedicationsChemotherapyMalignancyLeukemia